Dooney M, Saba T. Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme. Eur Respir J 2024;63:2301392.
PMID: 38423592